TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) annual meeting.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, 'We are pleased to present additional analyses from the ULTIMATE I & II Phase 3 trials and further in-vitro characterization of BRIUMVI at the AAN conference this week. We look forward to continuing to share additional exploratory analyses throughout the year.'
https://www.marketscreener.com/quote/stock/TG-THERAPEUTICS-INC-13314736/news/TG-Therapeutics-Announces-Presentation-of-Data-from-the-ULTIMATE-I-and-II-Phase-3-Trials-of-BRIUMVI-43646381/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.